A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
暂无分享,去创建一个
A. Grothey | M. Fakih | F. Ciardiello | S. Siena | F. Loupakis | K. Saxena | T. Yoshino | T. Nishina | Javier Rodríguez | K. Yamaguchi | K. Raghav | H. Kawakami | M. Bartolomeo | J. Shahidi | T. Masuishi | E. Yamamoto | E. Bako | Y. Okuda | E. Élez